Nepsis Capital Management Inc. Trims Position in Medtronic plc. (MDT)

Nepsis Capital Management Inc. lessened its position in shares of Medtronic plc. (NYSE:MDT) by 22.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 33,283 shares of the medical technology company’s stock after selling 9,412 shares during the quarter. Medtronic accounts for 1.4% of Nepsis Capital Management Inc.’s portfolio, making the stock its 29th biggest holding. Nepsis Capital Management Inc.’s holdings in Medtronic were worth $2,688,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of MDT. Schwab Charles Investment Management Inc. increased its position in Medtronic by 4.7% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 5,029,344 shares of the medical technology company’s stock worth $406,120,000 after buying an additional 227,449 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its position in Medtronic by 6.9% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 22,021 shares of the medical technology company’s stock worth $1,778,000 after buying an additional 1,421 shares in the last quarter. First National Trust Co increased its position in Medtronic by 12.5% in the fourth quarter. First National Trust Co now owns 39,135 shares of the medical technology company’s stock worth $3,160,000 after buying an additional 4,361 shares in the last quarter. Accredited Investors Inc. increased its position in Medtronic by 17.2% in the fourth quarter. Accredited Investors Inc. now owns 5,528 shares of the medical technology company’s stock worth $446,000 after buying an additional 810 shares in the last quarter. Finally, Creative Planning increased its position in Medtronic by 3.9% in the fourth quarter. Creative Planning now owns 101,019 shares of the medical technology company’s stock worth $8,157,000 after buying an additional 3,773 shares in the last quarter. Institutional investors own 81.75% of the company’s stock.

In other news, VP Richard Kuntz sold 78,526 shares of the company’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $86.21, for a total value of $6,769,726.46. Following the completion of the transaction, the vice president now owns 149,761 shares of the company’s stock, valued at $12,910,895.81. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Hooman Hakami sold 26,158 shares of the company’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $85.00, for a total value of $2,223,430.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 136,684 shares of company stock valued at $11,582,596. Corporate insiders own 0.31% of the company’s stock.

A number of analysts have commented on MDT shares. Needham & Company LLC reduced their price target on Medtronic from $95.00 to $94.00 and set a “buy” rating for the company in a research report on Tuesday, October 10th. SunTrust Banks set a $92.00 price target on Medtronic and gave the stock a “buy” rating in a research report on Sunday, November 19th. Cowen restated a “buy” rating and issued a $95.00 price target on shares of Medtronic in a research report on Friday, November 3rd. Jefferies Group restated a “buy” rating and issued a $96.00 price target on shares of Medtronic in a research report on Thursday, September 28th. Finally, Oppenheimer restated a “buy” rating and issued a $94.00 price target on shares of Medtronic in a research report on Wednesday, November 22nd. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and fifteen have given a buy rating to the company. Medtronic currently has a consensus rating of “Buy” and a consensus price target of $89.65.

Medtronic plc. (NYSE MDT) opened at $86.68 on Friday. The firm has a market capitalization of $118,106.23, a PE ratio of 23.75, a PEG ratio of 2.40 and a beta of 1.00. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.40 and a quick ratio of 2.05. Medtronic plc. has a one year low of $73.59 and a one year high of $89.72.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, November 21st. The medical technology company reported $1.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.99 by $0.08. The firm had revenue of $7.05 billion during the quarter, compared to analyst estimates of $7.05 billion. Medtronic had a return on equity of 12.63% and a net margin of 16.93%. The business’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.12 earnings per share. research analysts forecast that Medtronic plc. will post 4.77 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 19th. Stockholders of record on Friday, December 29th were paid a $0.46 dividend. This represents a $1.84 dividend on an annualized basis and a dividend yield of 2.12%. The ex-dividend date was Thursday, December 28th. Medtronic’s dividend payout ratio (DPR) is 50.41%.

ILLEGAL ACTIVITY WARNING: “Nepsis Capital Management Inc. Trims Position in Medtronic plc. (MDT)” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://stocknewstimes.com/2018/01/20/nepsis-capital-management-inc-trims-position-in-medtronic-plc-mdt.html.

Medtronic Profile

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc. (NYSE:MDT).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply